



## Nevada Oncology Prior Authorizations

Effective January 1, 2024, Optum Care will begin managing prior authorization requests for outpatient injectable chemotherapy, and related cancer therapies listed below.

- This change applies to all members with a cancer diagnosis in OCN-Nevada.
- Any active prior authorizations requested via the former process (Cancer Guidance Program) will remain in place.
- Prior authorization will continue to be required for outpatient injectable chemotherapy, and related cancer therapies.
- To submit an online request for prior authorization, sign into the Optum portal at [Provider Portal \(optum.com\)](https://optum.com)

Prior authorization/notification requests for plan members not listed above will continue to be requested through the existing process until future notice.

In general, the following chemotherapy drugs will require authorization:

- Injectable chemotherapy drugs (J9000 - J9999)
- Leucovorin (J0640) and Levoleucovorin (J0641/J0642)
- Injectable chemotherapy drugs that have a Q code
- Injectable chemotherapy drugs that have not yet received an assigned code and will be billed under a miscellaneous Healthcare Common Procedure Coding System (HCPCS) code will require prior authorization

Supportive therapies such as colony-stimulating factors, bone-modifying agents, and therapies used for prophylaxis or treat of emesis such as:

- Filgrastim, peg-filgrastim and biosimilar agents
- Aprepitant, palonosetron, and combination agents
- Zoledronic acid and denosumab

Additional resources are available here: [Provider Portal \(optum.com\)](https://optum.com)